Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $20.50.
Several research analysts recently issued reports on TLX shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Friday, September 25th. Citigroup reissued a "buy" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Wedbush restated an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday, October 21st. Royal Bank Of Canada raised Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research note on Monday, September 21st. Finally, Weiss Ratings upgraded Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st.
Check Out Our Latest Stock Report on TLX
Telix Pharmaceuticals Trading Down 3.4%
Shares of NASDAQ:TLX opened at $8.92 on Tuesday. The company's fifty day moving average price is $10.61 and its 200-day moving average price is $9.96. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11.
Hedge Funds Weigh In On Telix Pharmaceuticals
A number of large investors have recently modified their holdings of TLX. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the second quarter valued at approximately $1,731,000. XY Capital Ltd raised its stake in shares of Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company's stock worth $822,000 after acquiring an additional 58,739 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Telix Pharmaceuticals during the third quarter worth approximately $169,000. Private Advisor Group LLC raised its stake in shares of Telix Pharmaceuticals by 3.5% during the third quarter. Private Advisor Group LLC now owns 204,155 shares of the company's stock worth $2,240,000 after acquiring an additional 6,905 shares in the last quarter. Finally, WoodTrust Financial Corp bought a new stake in shares of Telix Pharmaceuticals in the 3rd quarter worth approximately $186,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals is an Australia-based biopharmaceutical company focused on developing and commercializing radiopharmaceuticals—medicines that use radioactive compounds to help diagnose or treat disease. Its programs primarily target cancer, including prostate, kidney and brain cancers. The company's commercial products include Illuccix, a kit used to prepare a radiotracer for prostate cancer imaging. Telix also has a development pipeline of imaging and therapeutic candidates, including programs designed to target prostate and kidney cancer.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.